- Home
- NMAI vs FDMT Comparison
NMAI vs FDMT Comparison
Compare NMAI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | FDMT |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.9M | 391.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMAI | FDMT |
|---|---|---|
| Price | $13.28 | $11.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 74.8K | ★ 911.8K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | $19.03 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $10.60 | $2.24 |
| 52 Week High | $12.55 | $12.34 |
Technical Indicators
Market Signals| Indicator | NMAI | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 54.86 |
| Support Level | $13.14 | $9.92 |
| Resistance Level | $13.27 | $11.89 |
| Average True Range (ATR) | 0.16 | 0.83 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 89.71 | 64.47 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.